ASCO 2026 to Highlight Global Shifts in Oncology Innovation
The upcoming ASCO 2026 conference is set to showcase significant global shifts in oncology innovation. Analysts have noted a growing trend of oncology assets originating from China, with nearly one-third of presentations at last year's conference involving Chinese-developed assets. This shift indicates a broader global distribution of oncology innovation, challenging traditional pharma models. The trend is reshaping industry assumptions, with China rapidly increasing its drug development and approval rates. By 2024, China had developed over 1,250 innovative drugs, surpassing Europe, and significantly reduced its regulatory review timelines. 
